Tumour-restricted post-translational modifications such as Tn (GalNAca1-o-Ser/Thr) and sialyl-Tn (STn) (NeuAca2-6-GalNAca1-O-Ser/Thr) are among the strategies for overcoming this obstacle [38]. The gene discussed is EEF1A2; the disease is neoplasm.